From Simple English Wikipedia, the free encyclopedia

Moderna is an American biotechnology company based in Cambridge, Massachusetts. They focus on drug discovery and development, and vaccine technologies based on messenger RNA.[1]

As of November 2020, Moderna was valued at $35 billion, and while none of its drugs had been approved, its COVID-19 vaccine candidate was close to being authorized for mass use.[2]

In 2023 it is to build a centre in Harwell, Oxfordshire, to produce vaccines for Covid, flu and respiratory syncytial virus.[3]

References[change | change source]

  1. Catherine Shaffer (December 6, 2013). "Moderna Makes Entrance with $40M Round for mRNA Work". BioWorld. Archived from the original on November 16, 2020. Retrieved Dec 11, 2013.
  2. Kuznia, Robert; Polglase, Katie; Mezzofiore, Gianluca (1 May 2020). "In quest for vaccine, US makes 'big bet' on company with unproven technology". CNN Investigates. Archived from the original on 16 November 2020. Retrieved 1 May 2020.
  3. "Moderna to build £150m vaccine centre in UK after NHS deal". Sunday Times. 5 March 2023. Archived from the original on 5 March 2023. Retrieved 8 March 2023.{{cite news}}: CS1 maint: bot: original URL status unknown (link)